Valuation: Nektar Therapeutics

Market Cap 2.39B 2.1B 1.95B 1.79B 3.37B 230B 3.42B 23.18B 9.05B 113B 8.97B 8.78B 391B P/E 2026 *
-7.85x
P/E 2027 * -6.52x
Enterprise Value 2.39B 2.1B 1.95B 1.79B 3.37B 230B 3.42B 23.18B 9.05B 113B 8.97B 8.78B 391B EV / Sales 2026 *
57.7x
EV / Sales 2027 * 64.6x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+1.97%
1 week+3.61%
Current month+1.31%
1 month+14.02%
3 months-22.86%
6 months+90.58%
Current year+67.28%
1 week 64.24
Extreme 64.24
73.68
1 month 62.58
Extreme 62.5801
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.02
Extreme 21.02
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
6/30/26 A Sell

Chief Technology Officer

-5,681 0.0168%
6/17/26 A Sell

Chief Executive Officer

-10,000 0.0296%
6/15/26 A Sell

Chief Technology Officer

-5,538 0.0164%
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+3.61%+182.90%+813.41% 2.39B
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.74%+1.51%+54.46%+231.81% 24.25B
Weighted average by Cap. -0.84%+2.11%+41.11%+140.19%

Financials

2026 *2027 *
Net sales 41.44M 36.4M 33.85M 31.06M 58.37M 3.99B 59.27M 402M 157M 1.96B 156M 152M 6.78B 36.99M 32.49M 30.21M 27.72M 52.09M 3.56B 52.89M 359M 140M 1.75B 139M 136M 6.05B
Net income -249M -219M -204M -187M -351M -23.99B -356M -2.42B -944M -11.8B -935M -915M -40.79B -351M -308M -287M -263M -494M -33.78B -502M -3.4B -1.33B -16.61B -1.32B -1.29B -57.42B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
24/07/26 $70.73 +1.97% 836,066
23/07/26 $69.36 +0.06% 631,124
22/07/26 $69.32 +0.95% 508,631
21/07/26 $68.67 +5.91% 1,294,048
20/07/26 $64.84 -5.01% 748,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
70.72USD
Average target price
153.22USD
Spread / Average Target
+116.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock